Dara Biosciences (DARA) 0.79 $DARA
DARA BioSciences Granted Waiver of Product and Establishment Fees by the FDA
Marketwired - Tue Jan 06, 7:03AM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it has been granted a "barrier-to-innovation" waiver for certain product and establishment fees.
DARA: 0.79 (unch)
Biotech Weekly: Top Value Biotech Picks For 2015
Daniel Ward - at Seeking Alpha - Mon Jan 05, 8:01AM CST
ROSG: 3.65 (+0.32), ECYT: 5.26 (-0.02), TRGT: 2.50 (-0.01), OGXI: 2.06 (-0.05), BOTA: 2.60 (-0.06), XBI: 203.40 (+1.36), DARA: 0.79 (unch), RGDO: 1.17 (+0.02), REPH: 3.13 (-0.12)
Biotech Weekly: A Few Rules And Regulations Affecting Biotech Investors
Daniel Ward - Seeking Alpha - Mon Dec 22, 11:57AM CST
The biotech sector continued its amazing year this week with both the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB ) and the SPDR S&P Biotech ETF (NYSEARCA: XBI ) closing the week up 3.6%. The popular IBB is now up 39.7% just this year while the...
NERV: 4.68 (+0.09), XBI: 203.40 (+1.36), DARA: 0.79 (unch), AEZS: 0.53 (unch)
Dara Biosciences: An Attractive Small-Cap Breast Cancer Stock With Potential Catalysts
Daniel Ward - at Seeking Alpha - Fri Dec 12, 3:52PM CST
DARA: 0.79 (unch)
DARA Biosciences' CEO Christopher Clement on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 12:55PM CST
DARA: 0.79 (unch)
DARA Biosciences Q3 EPS of -$0.11
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:28PM CST
DARA: 0.79 (unch)
DARA BioSciences Announces Third Quarter 2014 Results
Marketwired - Wed Nov 05, 3:17PM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2014 results.
DARA: 0.79 (unch)
DARA BioSciences Continues to Support Patient Outreach and Education in Conjunction With Breast Cancer Awareness Month
Marketwired - Fri Oct 31, 7:01AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced its continued support of patient education and outreach to support Breast Cancer Awareness Month.
DARA: 0.79 (unch)
DARA BioSciences Announces Date and Time for Announcement of Third Quarter 2014 Results
Marketwired - Wed Oct 29, 7:08AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will release financial results for the third quarter ended September 30, 2014, after the close of the market on Wednesday, November 5, 2014.
DARA: 0.79 (unch)
DARA BioSciences Petitions FDA to Amend Label for Tamoxifen Citrate and Soltamox® to Extend Duration of Adjuvant Therapy to 10 Years
Marketwired - Wed Oct 29, 5:02AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals with a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today petitioned the U.S. Food and Drug Administration (FDA) to amend the label for tamoxifen citrate and Soltamox® (tamoxifen citrate), the only FDA-approved liquid bioequivalent of tamoxifen, by increasing the recommended duration of adjuvant therapy for women with estrogen receptor-positive breast cancer from five to 10 years.
DARA: 0.79 (unch)
DARA BioSciences Supports Breastcancer.org to Increase Awareness and Raise Funds to Fight Breast Cancer
Marketwired - Fri Oct 24, 7:02AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced it is supporting Breastcancer.org with its Sponsor level commitment to BREASTCANCER.ORG's 5th Annual ROCK the RIBBON Black & White Party. Breastcancer.org is a leading resource for breast health and breast cancer information and support.
DARA: 0.79 (unch)
DARA BioSciences Product Gelclair(R) Attains Market Leadership Position in U.S. Retail Market
Marketwired - Tue Oct 14, 6:02AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced today that its product, Gelclair®, indicated for the management of oral mucositis, has attained a major milestone in the U.S. market by becoming the number one oral gel barrier prescription product in the retail sector.
DARA: 0.79 (unch)
DARA BioSciences Announces Participation at the Aegis Capital Corporation Healthcare and Technology Conference in Las Vegas
Marketwire - Thu Sep 11, 9:02AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the Aegis Capital Corporation Healthcare and Technology Conference. The conference is being held September 10-13, 2014, at the Encore at Wynn Las Vegas Hotel in Las Vegas.
DARA: 0.79 (unch)
DARA BioSciences Announces Participation at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10, 2014
Marketwire - Wed Sep 03, 7:06AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at the New York Park Palace Hotel in New York City.
DARA: 0.79 (unch)
DARA BioSciences Announces Date and Time for Announcement of Second Quarter 2014 Results
Marketwire - Tue Aug 05, 3:06PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will release financial results for the second quarter ended June 30, 2014, after the close of the market on Tuesday, August 12, 2014.
DARA: 0.79 (unch)
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Jul 11, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
AVNR: 16.96 (unch), DARA: 0.79 (unch), MEIP: 5.00 (-0.04)
5 Stocks Under $10 Set to Soar Higher
at The Street - Mon Jul 07, 7:37AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
BEBE: 3.90 (+0.01), ONE: 3.49 (-0.01), DARA: 0.79 (unch), ORBC: 5.83 (+0.21), UPIP: 0.78 (+0.01)
Agreements, Orphan Drug Designations, and Management Changes - Analyst Notes on Medtronic, DARA BioSciences, Sequenom, AcelRx and Pernix
PR Newswire - Thu Jun 19, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), DARA BioSciences, Inc (NASDAQ: DARA), Sequenom Inc. (NASDAQ: SQNM), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) and Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3874-100free.
ACRX: 7.29 (-0.06), SQNM: 3.62 (unch), MDT: 75.26 (+0.33), PTX: 8.63 (+0.01), DARA: 0.79 (unch)
DARA BioSciences Announces Leadership Transition
Marketwire - Wed Jun 18, 1:35AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, today announced that its Board of Directors has appointed current President and Chief Operating Officer (COO) Christopher G. Clement to President and Chief Executive Officer (CEO), effective immediately. David J. Drutz, M.D., the Company's current CEO and Chief Medical Officer (CMO), will transition to the Executive Chairman of the Board of Directors while continuing to serve as CMO. In these roles, Dr. Drutz will provide ongoing leadership to DARA's strategic planning, business development and educational product support activities relative to our customers and sales organization. Haywood D. Cochrane Jr. will assume the role of Vice Chairman.
DARA: 0.79 (unch)
DARA BioSciences Granted Waiver of Product and Establishment Fees by the FDA
Marketwired - Tue Jan 06, 7:03AM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it has been granted a "barrier-to-innovation" waiver for certain product and establishment fees.
DARA: 0.79 (unch)
Biotech Weekly: Top Value Biotech Picks For 2015
Daniel Ward - at Seeking Alpha - Mon Jan 05, 8:01AM CST
ROSG: 3.65 (+0.32), ECYT: 5.26 (-0.02), TRGT: 2.50 (-0.01), OGXI: 2.06 (-0.05), BOTA: 2.60 (-0.06), XBI: 203.40 (+1.36), DARA: 0.79 (unch), RGDO: 1.17 (+0.02), REPH: 3.13 (-0.12)
Biotech Weekly: A Few Rules And Regulations Affecting Biotech Investors
Daniel Ward - Seeking Alpha - Mon Dec 22, 11:57AM CST
The biotech sector continued its amazing year this week with both the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB ) and the SPDR S&P Biotech ETF (NYSEARCA: XBI ) closing the week up 3.6%. The popular IBB is now up 39.7% just this year while the...
NERV: 4.68 (+0.09), XBI: 203.40 (+1.36), DARA: 0.79 (unch), AEZS: 0.53 (unch)
Dara Biosciences: An Attractive Small-Cap Breast Cancer Stock With Potential Catalysts
Daniel Ward - at Seeking Alpha - Fri Dec 12, 3:52PM CST
DARA: 0.79 (unch)
DARA Biosciences' CEO Christopher Clement on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 12:55PM CST
DARA: 0.79 (unch)
DARA Biosciences Q3 EPS of -$0.11
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:28PM CST
DARA: 0.79 (unch)
DARA BioSciences Announces Third Quarter 2014 Results
Marketwired - Wed Nov 05, 3:17PM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2014 results.
DARA: 0.79 (unch)
DARA BioSciences Continues to Support Patient Outreach and Education in Conjunction With Breast Cancer Awareness Month
Marketwired - Fri Oct 31, 7:01AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced its continued support of patient education and outreach to support Breast Cancer Awareness Month.
DARA: 0.79 (unch)
DARA BioSciences Announces Date and Time for Announcement of Third Quarter 2014 Results
Marketwired - Wed Oct 29, 7:08AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will release financial results for the third quarter ended September 30, 2014, after the close of the market on Wednesday, November 5, 2014.
DARA: 0.79 (unch)
DARA BioSciences Petitions FDA to Amend Label for Tamoxifen Citrate and Soltamox® to Extend Duration of Adjuvant Therapy to 10 Years
Marketwired - Wed Oct 29, 5:02AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals with a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today petitioned the U.S. Food and Drug Administration (FDA) to amend the label for tamoxifen citrate and Soltamox® (tamoxifen citrate), the only FDA-approved liquid bioequivalent of tamoxifen, by increasing the recommended duration of adjuvant therapy for women with estrogen receptor-positive breast cancer from five to 10 years.
DARA: 0.79 (unch)
DARA BioSciences Supports Breastcancer.org to Increase Awareness and Raise Funds to Fight Breast Cancer
Marketwired - Fri Oct 24, 7:02AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced it is supporting Breastcancer.org with its Sponsor level commitment to BREASTCANCER.ORG's 5th Annual ROCK the RIBBON Black & White Party. Breastcancer.org is a leading resource for breast health and breast cancer information and support.
DARA: 0.79 (unch)
DARA BioSciences Product Gelclair(R) Attains Market Leadership Position in U.S. Retail Market
Marketwired - Tue Oct 14, 6:02AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced today that its product, Gelclair®, indicated for the management of oral mucositis, has attained a major milestone in the U.S. market by becoming the number one oral gel barrier prescription product in the retail sector.
DARA: 0.79 (unch)
DARA BioSciences Announces Participation at the Aegis Capital Corporation Healthcare and Technology Conference in Las Vegas
Marketwire - Thu Sep 11, 9:02AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the Aegis Capital Corporation Healthcare and Technology Conference. The conference is being held September 10-13, 2014, at the Encore at Wynn Las Vegas Hotel in Las Vegas.
DARA: 0.79 (unch)
DARA BioSciences Announces Participation at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10, 2014
Marketwire - Wed Sep 03, 7:06AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at the New York Park Palace Hotel in New York City.
DARA: 0.79 (unch)
DARA BioSciences Announces Date and Time for Announcement of Second Quarter 2014 Results
Marketwire - Tue Aug 05, 3:06PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will release financial results for the second quarter ended June 30, 2014, after the close of the market on Tuesday, August 12, 2014.
DARA: 0.79 (unch)
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Jul 11, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
AVNR: 16.96 (unch), DARA: 0.79 (unch), MEIP: 5.00 (-0.04)
5 Stocks Under $10 Set to Soar Higher
at The Street - Mon Jul 07, 7:37AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
BEBE: 3.90 (+0.01), ONE: 3.49 (-0.01), DARA: 0.79 (unch), ORBC: 5.83 (+0.21), UPIP: 0.78 (+0.01)
Agreements, Orphan Drug Designations, and Management Changes - Analyst Notes on Medtronic, DARA BioSciences, Sequenom, AcelRx and Pernix
PR Newswire - Thu Jun 19, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), DARA BioSciences, Inc (NASDAQ: DARA), Sequenom Inc. (NASDAQ: SQNM), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) and Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3874-100free.
ACRX: 7.29 (-0.06), SQNM: 3.62 (unch), MDT: 75.26 (+0.33), PTX: 8.63 (+0.01), DARA: 0.79 (unch)
DARA BioSciences Announces Leadership Transition
Marketwire - Wed Jun 18, 1:35AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, today announced that its Board of Directors has appointed current President and Chief Operating Officer (COO) Christopher G. Clement to President and Chief Executive Officer (CEO), effective immediately. David J. Drutz, M.D., the Company's current CEO and Chief Medical Officer (CMO), will transition to the Executive Chairman of the Board of Directors while continuing to serve as CMO. In these roles, Dr. Drutz will provide ongoing leadership to DARA's strategic planning, business development and educational product support activities relative to our customers and sales organization. Haywood D. Cochrane Jr. will assume the role of Vice Chairman.
DARA: 0.79 (unch)
